Heron Therapeutics, Inc. (NASDAQ:HRTX) traded down 0% during mid-day trading on Friday . The company traded as low as $16.30 and last traded at $16.35. 2,356,124 shares changed hands during mid-day trading, an increase of 188% from the average session volume of 817,789 shares. The stock had previously closed at $16.35.
A number of equities research analysts have recently issued reports on the stock. BidaskClub cut shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 18th. Noble Financial reaffirmed a “buy” rating on shares of Heron Therapeutics in a research report on Thursday, August 10th. Cantor Fitzgerald set a $31.00 price objective on shares of Heron Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 18th. Zacks Investment Research raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, Mizuho reaffirmed a “buy” rating and set a $28.00 price objective on shares of Heron Therapeutics in a research report on Tuesday, November 7th. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company’s stock. Heron Therapeutics currently has an average rating of “Buy” and a consensus target price of $28.36.
The company has a debt-to-equity ratio of 0.62, a current ratio of 2.12 and a quick ratio of 2.72.
Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative return on equity of 385.11% and a negative net margin of 831.89%. The company had revenue of $8.57 million during the quarter, compared to the consensus estimate of $8.12 million. sell-side analysts expect that Heron Therapeutics, Inc. will post -3.42 earnings per share for the current fiscal year.
A number of hedge funds have recently made changes to their positions in the stock. Janus Henderson Group PLC bought a new stake in Heron Therapeutics in the second quarter valued at approximately $78,134,000. Vanguard Group Inc. boosted its holdings in Heron Therapeutics by 11.8% in the second quarter. Vanguard Group Inc. now owns 2,096,465 shares of the biotechnology company’s stock valued at $29,036,000 after acquiring an additional 221,362 shares during the last quarter. State Street Corp boosted its holdings in Heron Therapeutics by 30.7% in the first quarter. State Street Corp now owns 1,787,678 shares of the biotechnology company’s stock valued at $26,822,000 after acquiring an additional 420,113 shares during the last quarter. Rubric Capital Management LP boosted its holdings in Heron Therapeutics by 6.3% in the second quarter. Rubric Capital Management LP now owns 1,700,000 shares of the biotechnology company’s stock valued at $23,545,000 after acquiring an additional 100,000 shares during the last quarter. Finally, Balyasny Asset Management LLC boosted its holdings in Heron Therapeutics by 2.1% in the second quarter. Balyasny Asset Management LLC now owns 1,221,403 shares of the biotechnology company’s stock valued at $16,916,000 after acquiring an additional 24,688 shares during the last quarter.
ILLEGAL ACTIVITY WARNING: This article was first published by Transcript Daily and is owned by of Transcript Daily. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://transcriptdaily.com/2017/11/12/heron-therapeutics-inc-hrtx-stock-price-down-0.html.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.